An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Atezolizumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms IMbrella C
- Sponsors Roche
- 07 Nov 2023 Parallel has been added to the design terms.
- 12 Jan 2023 Planned End Date changed from 21 Nov 2025 to 31 Dec 2025.
- 12 Jan 2023 Planned primary completion date changed from 21 Nov 2025 to 31 Dec 2025.